Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.
ORIC Pharmaceuticals, Inc. (ORIC) is a clinical-stage biopharmaceutical company pioneering therapies to combat cancer treatment resistance. This news hub provides investors and researchers with timely updates on clinical developments, strategic partnerships, and scientific breakthroughs in precision oncology.
Access consolidated information about ORIC's progress in developing small molecule inhibitors targeting hormone-dependent cancers and resistant tumor mechanisms. The page serves as a historical archive and current awareness tool for tracking milestones in therapeutic innovation.
Key updates include:
Clinical trial advancements for oral therapies addressing treatment-refractory cancers
Research collaborations leveraging AI-driven drug discovery platforms
Regulatory milestones and FDA designations for novel oncology candidates
Bookmark this page for streamlined monitoring of ORIC's progress in overcoming cancer resistance through targeted therapeutic strategies. Check regularly for verified updates directly tied to the company's public disclosures.
ORIC Pharmaceuticals has entered into an exclusive license agreement with Voronoi for the development of ORIC-114, a selective inhibitor targeting EGFR and HER2 exon 20 insertion mutations. ORIC-114 is designed for brain penetrance and aims to address a critical unmet medical need, particularly in patients with brain metastases. ORIC will initiate a global Phase 1/2 trial in the second half of 2021, having paid $5 million in cash and $8 million in stock, along with potential milestone payments totaling up to $608 million. This partnership enhances ORIC's pipeline in precision oncology.
On October 9, 2020, ORIC Pharmaceuticals announced a presentation at the 32nd EORTC-NCI-AACR Symposium, showcasing preclinical data on ORIC-101, a glucocorticoid receptor antagonist. The study demonstrates ORIC-101's ability to combat GR-mediated resistance in prostate cancer cell lines treated with androgen receptor degraders. ORIC-101 is currently in two Phase 1b trials, one with enzalutamide in metastatic prostate cancer and another with nab-paclitaxel in advanced solid tumors. Interim data is expected in 2021.
ORIC Pharmaceuticals (Nasdaq: ORIC) announced participation in key investor conferences in September 2020. CEO Jacob Chacko will join the Citi's 15th Annual BioPharma Virtual Conference on September 9, and present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15. Additionally, ORIC will host virtual meetings at the 2020 Cantor Virtual Global Healthcare Conference on September 17 and participate in a fireside chat at the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on September 22. Webcasts will be available on the company's website.
ORIC Pharmaceuticals reported significant progress in its clinical pipeline, including the anticipated IND filings for PRC2 inhibitor ORIC-944 and CD73 inhibitor ORIC-533 in 2021. Financial results for Q2 2020 showed cash and equivalents at $196.6 million, bolstered by an IPO that raised $138 million. R&D expenses rose to $7.7 million, and G&A expenses increased to $3.4 million, reflecting higher operational costs. The company is focused on advancing its projects, with plans for interim data readouts scheduled for the upcoming year.
ORIC Pharmaceuticals has secured exclusive worldwide rights to develop and commercialize a novel PRC2 inhibitor through a licensing agreement with Mirati Therapeutics. The compound, ORIC-944, is targeted for prostate cancer treatment and is positioned as potentially best-in-class. ORIC plans to file an IND for ORIC-944 in the second half of 2021. In exchange for the license, ORIC issued a one-time non-cash payment of $20 million in ORIC common stock, based on a share price of $34.00, with no future milestone or royalty obligations.
ORIC Pharmaceuticals (Nasdaq: ORIC) announced a conference call on August 5, 2020, at 4:30 p.m. ET to discuss second quarter 2020 financial results and business highlights. Participants can join by dialing (866) 393-4306 or (734) 385-2616 for international calls, using conference ID: 5167646. The event will also be available via live webcast on the company's website, which will remain archived for 60 days. ORIC focuses on innovative oncology treatments aimed at overcoming therapeutic resistance, with lead candidate ORIC-101 currently in Phase 1b trials.
ORIC Pharmaceuticals presented encouraging preclinical data for its ORIC-101 glucocorticoid receptor antagonist and ORIC-533 CD73 inhibitor at the AACR Virtual Annual Meeting II. ORIC-101 showed the ability to reverse GR-mediated resistance across various tumor models, which is critical in cancer treatment. The ongoing Phase 1b trials with enzalutamide and nab-paclitaxel aim to further assess its effectiveness. Meanwhile, ORIC-533 has demonstrated notable potency in inhibiting adenosine production, with potential benefits for immunotherapy and anti-tumor responses.
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) appointed Dr. Lori Kunkel to its board of directors, enhancing its expertise in oncology and immunology. Dr. Kunkel, with over twenty-five years of experience, has played a pivotal role in the development and commercialization of various oncology therapies. CEO Jacob Chacko expressed enthusiasm for her contributions as the company advances its lead asset, ORIC-101, in clinical development. ORIC-101 is currently being tested in two Phase 1b trials, showcasing the company's commitment to overcoming therapeutic resistance in cancer.
ORIC Pharmaceuticals, a clinical-stage oncology company, will have its CEO, Jacob Chacko, present at the Jefferies Virtual Healthcare Conference on June 2, 2020, at 11:00 am ET. The company focuses on developing therapies to combat therapeutic resistance in cancer. Its lead candidate, ORIC-101, is currently undergoing Phase 1b trials in conjunction with Xtandi and Abraxane. A webcast of the presentation will be available via the investor section of their website, with a replay accessible for 90 days afterward.
ORIC Pharmaceuticals successfully completed a $138 million initial public offering, increasing its cash reserves to $204.2 million as of April 30. The funds are expected to support operations into 2023. Key developments include the first patient dosed in the ORIC-101 Phase 1b trial and promising preclinical data on the CD73 inhibitor ORIC-533. The company also strengthened its leadership team with new appointments. ORIC anticipates crucial data readouts in 2021 and plans to file for an IND for ORIC-533 in the first half of 2021.
FAQ
What is the current stock price of Oric Pharmaceuticals (ORIC)?
What is the market cap of Oric Pharmaceuticals (ORIC)?
